.png)
Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy
New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations CINCINNATI--(BUSINESS WIRE)--National Resilience...
BLOG
Read on
%201.png)
Navigating the Evolving Landscape of Fill/Finish: Trends, Challenges, and What’s Ahead
A Q&A with Nithin Stephen As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities...
Cell Therapy Innovations: Reducing Costs to Improve Patient Access
Cell therapies offer life-changing treatments for patients with limited options, but face commercialization challenges due to high costs, ability to...
Executive Interview: Advancing Therapies That Transform Lives
Drug Development & Delivery recently interviewed Susan Billings, Ph.D., Chief Commercial Officer of Resilience, to discuss pressing issues in the...
Presentation: Rapid Multi-Omics Cell Therapy Characterization and QC
On February 5th at 1:00 pm, join Neeraj Salathia, Director of Advanced Genomics, for a presentation on Rapid Multi-Omics Cell Therapy...
Whitepaper: 3-Day Short Cycle CAR-T Manufacturing Process
The conventional manufacturing process for the generation of activated CAR-T cells can typically take 7 to 9 days or even longer. Resilience has...
Presentation: Expedited Cell Therapy QC: Sample in, to QC Report in 48 Hours
On January 22nd at 4:00 pm, join Mazen Karaman, Director of Platform Management – Cell Therapy, for a presentation on Expedited Cell Therapy QC.
.png)
On-Demand Webinar: Outsourced Pharma Capacity Update - Drug Substance
Are you an innovative company seeking a reliable CDMO partner to help move your drug substance program to its next phase of success? Look no further.
